• Phare
  • Validé par KD/KO

Anticorps Polyclonal de lapin anti-NCOA4

NCOA4 Polyclonal Antibody for IHC, IF/ICC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, souris et plus (1)

Applications

IHC, IF/ICC, ELISA

Conjugaison

Non conjugué

Publications(3)

N° de cat : 10968-1-AP

Synonymes

70 kDa AR activator, 70 kDa AR-activator, Androgen receptor-associated protein of 70 kDa, ARA70, ELE1



Applications testées

Résultats positifs en IHCtissu cérébral de souris,
il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
Résultats positifs en IF/ICCcellules MCF-7,

Dilution recommandée

ApplicationDilution
Immunohistochimie (IHC)IHC : 1:400-1:1600
Immunofluorescence (IF)/ICCIF/ICC : 1:200-1:800
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

10968-1-AP cible NCOA4 dans les applications de IHC, IF/ICC, ELISA et montre une réactivité avec des échantillons Humain, souris

Réactivité Humain, souris
Réactivité citéerat, Humain, souris
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène NCOA4 Protéine recombinante Ag1408
Nom complet nuclear receptor coactivator 4
Masse moléculaire calculée 70 kDa
Numéro d’acquisition GenBankBC012736
Symbole du gène NCOA4
Identification du gène (NCBI) 8031
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS with 0.02% sodium azide and 50% glycerol
Conditions de stockageStocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Nuclear receptor coactivator 4 (NCOA4) also named androgen receptor (AR) coactivator ARA70, RFG and ELE1, is a putative co-activator that specifically enhances the activity of the androgen receptor. In human thyroid carcinomas, the Ret proto-oncogene fuses to ARA70 to form Ret/PTC3 by an intrachromosomal inversion of chromosome 10 in vivo. ARA70a can function as a ligand-enhanced co-activator of PPARg in adipocytes. However, PPARg-ARA70 transactivation can be squelched by AR, which suggests cross talk between PPARg- and AR-mediated response. ARA70a has no intrinsic transcription activation domain or histone acetyltransferase activity, but it interacts with histone acetyltransferase, p/CAF, CBP and p300/CBP-associated factors, and the basal transcription factor TFIIB. The interaction between ARA70 and AR occurs through the ligand-binding domain. The presence of ARA70 can enhance the androgenic activity of 17-b Estradiol (E2) and antiandrogens toward AR. ARA70 may be involved in prostate carcinogenesis and ovarian cancer and may serve as a key mediator of estrogen-androgen synergism.There are several isoforms of ZGPAT that are produced as a result of alternative splicing events. ARA70a is widely expressed, and its expression is highest in testis and adipose tissues, whereas ARA70b (The shorter variant, results from an internal 985-bp deletion.) is solely expressed in the testis.This antibody is a rabbit polyclonal antibody raised against the N-400aa of human NCOA4 protein.

Protocole

Product Specific Protocols
IHC protocol for NCOA4 antibody 10968-1-APDownload protocol
IF protocol for NCOA4 antibody 10968-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
ratIF

J Transl Med

RBX1 mitigates ferroptosis by inhibiting NCOA4-mediated ferritinophagy and contributes to the attenuation of intervertebral disc degeneration

Authors - Lu-Ping Zhou
mouse

Inflammation

Nrg4 Secreted by Brown Adipose Tissue Suppresses Ferroptosis of Sepsis-Induced Liver Injury

Authors - Linqi Feng
human

J Control Release

Metal phenolic networks-driven bufalin homodimeric prodrug nano-coassemblies for ferroptosis-augmented tumor therapy

Authors - Fei Wu
{{ptg:RelatedPrimaryAntibodies}}